Xydalba 500 mg powder for concentrate for solution for infusion

DRUG3 trials

Sponsors

Assistance Publique Hopitaux De Paris, Centre Hospitalier Universitaire De Nice, Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH

Conditions

Acute bacterial skin and skin structure infection (ABSSSI) ErysipelasCatheter related bloodstream infections due to Staphylococcus aureusprosthetic joint infections

Phase 2

Efficacy of dalbavancin in osteoarticular infections associated with hip, knee and shoulder prostheses PRO-DALBA

Active, not recruitingCTIS2024-518183-12-00

Centre Hospitalier Universitaire De Niceprosthetic joint infections

Start: 2022-03-07Target: 43Updated: 2025-08-08

Phase 3

Randomized open-label controlled trial evaluating a single-dose intravenous Dalbavancin versus standard antibiotic therapy during catheterrelated bloodstream infections due to Staphylococcus aureus [DALICATH]

RecruitingCTIS2024-514952-34-00

Assistance Publique Hopitaux De ParisCatheter related bloodstream infections due to Staphylococcus aureus

Start: 2023-06-23Target: 406Updated: 2025-04-23

Phase 4

Pilot Study - Safety and Efficacy of Dalbavancin in Early Outpatient Treatment of Erysipelas and Limited Cellulitis

Not yet recruitingCTIS2025-524877-18-00

Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbHAcute bacterial skin and skin structure infection (ABSSSI) Erysipelas

Target: 50Updated: 2026-04-07